Crossmark

Effects of the introduction of biosimilars on the costs and prescription frequency of selected biologics in statutory and private health insurance in Germany: differences and similarities

Crossref DOI link: https://doi.org/10.1007/s10389-025-02429-w

Published Online: 2025-02-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Oppel, Susanne

Renner, Bertold

Elsner, Sarah

Lippert, Annemarie https://orcid.org/0000-0002-5661-5376
Funding

Funding for this research was provided by:

Technische Universität Dresden
License Information

Text and Data Mining valid from 2025-02-17

Version of Record valid from 2025-02-17
More Information

Article History

Received: 28 August 2024

Accepted: 27 January 2025

First Online: 17 February 2025

Declarations

:

: This article does not contain any studies with human participants or animals performed by the authors. Approval from the Ethics Committee at the Dresden University of Technology has been received (November 27th, 2020, No. BO-EK-518112020).

: Not applicable.

: Not applicable.

: The authors declare that they have no conflicts of interests.

Document is current

Any future updates will be listed below